isoprinosine 500mg tableta
ewopharma international, s.r.o., bratislava array - 4671 inosin pranobex - tableta - 500mg - inosin pranobex
clarithromycin hameln 500mg prášek pro koncentrát pro infuzní roztok
hameln pharma gmbh, hameln array - 21650 klarithromycin-laktobionÁt - prášek pro koncentrát pro infuzní roztok - 500mg - klarithromycin
clarithromycin tillomed 500mg prášek pro koncentrát pro infuzní roztok
tillomed pharma gmbh, schönefeld array - 21650 klarithromycin-laktobionÁt - prášek pro koncentrát pro infuzní roztok - 500mg - klarithromycin
fromilid 125mg/5ml granule pro perorální suspenzi
krka, d.d., novo mesto, novo mesto array - 10815 klarithromycin - granule pro perorální suspenzi - 125mg/5ml - klarithromycin
fromilid 250mg potahovaná tableta
krka, d.d., novo mesto, novo mesto array - 10815 klarithromycin - potahovaná tableta - 250mg - klarithromycin
fromilid 500mg potahovaná tableta
krka, d.d., novo mesto, novo mesto array - 10815 klarithromycin - potahovaná tableta - 500mg - klarithromycin
fromilid uno 500mg tableta s řízeným uvolňováním
krka, d.d., novo mesto, novo mesto array - 10815 klarithromycin - tableta s řízeným uvolňováním - 500mg - klarithromycin
nucala
glaxosmithkline trading services - mepolizumab - astma - léky na obstrukční onemocnění dýchacích cest, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - přípravky proti dermatitidě, kromě kortikosteroidů - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
xolair
novartis europharm limited - omalizumab - asthma; urticaria - léky na obstrukční onemocnění dýchacích cest, - alergické asthmaxolair je indikován u dospělých, dospívajících a dětí (6 až.